Trial · NCT04401293
Results by group14
Each measurement the trial posted, group by group, in the words and numbers it posted.
1 to 14 of 14
Download this page as JSON| Outcome | Group | Category | Value | Spread | Units |
|---|---|---|---|---|---|
| Composite Outcome of Arterial Thromboembolic Events, Venous Thromboembolic Events and All-cause Mortality at Day 30 ± 2 Days. | Full Dose LMWH Anticoagulation Therapy | 25 | Participants | ||
| Composite Outcome of Arterial Thromboembolic Events, Venous Thromboembolic Events and All-cause Mortality at Day 30 ± 2 Days. | Prophylactic/Intermediate Dose LMWH or UFH Therapy | 31 | Participants | ||
| Major Bleeding | Full Dose LMWH Anticoagulation Therapy | 6 | Participants | ||
| Major Bleeding | Prophylactic/Intermediate Dose LMWH or UFH Therapy | 2 | Participants | ||
| Composite Outcome of Arterial Thromboembolic Events, Venous Thromboembolic Events and All-cause Mortality at Hospital Day 10 + 4 | Full Dose LMWH Anticoagulation Therapy | 2 | Participants | ||
| Composite Outcome of Arterial Thromboembolic Events, Venous Thromboembolic Events and All-cause Mortality at Hospital Day 10 + 4 | Prophylactic/Intermediate Dose LMWH or UFH Therapy | 3 | Participants | ||
| Sepsis-induced Coagulopathy (SIC) Score | Full Dose LMWH Anticoagulation Therapy | 2.35 | Standard Deviation 0.73 | units on a scale | |
| Sepsis-induced Coagulopathy (SIC) Score | Prophylactic/Intermediate Dose LMWH or UFH Therapy | 2.31 | Standard Deviation 0.85 | units on a scale | |
| Progression to Acute Respiratory Distress Syndrome (ARDS) | Full Dose LMWH Anticoagulation Therapy | 11 | Participants | ||
| Progression to Acute Respiratory Distress Syndrome (ARDS) | Prophylactic/Intermediate Dose LMWH or UFH Therapy | 6 | Participants | ||
| Need for Intubation | Full Dose LMWH Anticoagulation Therapy | 17 | Participants | ||
| Need for Intubation | Prophylactic/Intermediate Dose LMWH or UFH Therapy | 21 | Participants | ||
| Re-hospitalization | Full Dose LMWH Anticoagulation Therapy | 1 | Participants | ||
| Re-hospitalization | Prophylactic/Intermediate Dose LMWH or UFH Therapy | 3 | Participants |
Source ClinicalTrials.govtrials-2026-11-12-0.5.0
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/trials/v1/NCT04401293/results